Novel Predictive Biomarkers Based on Non-coding RNAs in Corpus Cancer Immunotherapy

Due to variances in personal genetic fingerprints, the complexity of the tumor microenvironment, and epigenetic on-mechanisms, establishing clinical predictive biomarkers for the purpose of evaluating the response to immunotherapy continues to be a difficult challenge at the present time. Main body: The early monitoring of critical non-coding RNA (ncRNA) biomarkers has the potential to assist in the prediction of the clinical success of cancer immunotherapy and the development of standard predictive ncRNA biomarkers. According to one example, a decrease in the level of miR-۱۲۵b-۵p in the plasma of patients with non-small cell lung cancer who were treated with anti-PD-۱ is indicative of a favorable prognosis. The presence of microRNA-۱۵۳ in the plasma of patients with colorectal cancer who have been treated with chimeric antigen receptor T lymphocyte (CAR-T) cell treatment may be an indication of the activation of T-cell killing activity. There is a possibility that the levels of miR-۱۴۸a-۳p and miR-۳۷۵ can predict positive responses to CAR-T-cell treatment in patients with B-cell acute lymphoblastic leukemia. It has been shown that blood levels of miR-۱۲۲۸-۵p, miR-۱۹۳a-۵p, and miR-۳۷۵-۳p are predictive biomarkers of a favorable response and better overall survival in cancer patients who have been treated with the GPC۳ peptide vaccine. As a result, there is an urgent requirement for additional research to be conducted in order to provide more information on the major non-coding RNA biomarkers that have the capability of predicting early clinical responses to immunotherapy. Conclusion: The purpose of this article is to provide a comprehensive assessment of the significant and innovative predictive non-coding RNA biomarkers that have been identified in cancer patients who have been treated with various immunotherapeutic modalities. These modalities include monoclonal antibodies, small chemical inhibitors, cancer vaccines, and CAR-T cells. A succinct discussion on impending prospects is also offered, defining technical techniques for the optimal exploitation of immunomodulatory ncRNA biomarkers as prognostic tools and therapeutic targets. This is included in the article.

کلیدواژه ها:

Biomarker ، Nin-coding ، corpus cancer